TROP2 CAR/IL-15 NK Cells for Oral Premalignant Lesions

The trial aims to test a new treatment using specially modified immune cells called TROP2 CAR/IL-15 NK cells, a type of cell therapy. These cells target and treat high-risk oral premalignant lesions, which are abnormal growths in the mouth that can potentially become cancerous. The trial will evaluate the safety and initial effectiveness of the treatment. It suits individuals with visible, measurable oral lesions, such as leukoplakia or erythroplakia, who have been diagnosed with specific types of oral abnormalities. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

The trial requires that you stop taking cytotoxic chemotherapy at least 2 weeks before, targeted therapies 3 days before, and any cell therapy 3 months before joining. The protocol does not specify other medications, so it's best to discuss your current medications with the study team.

Studies are exploring the safety of a new treatment using specially modified immune cells called TROP2 CAR/IL-15 TGFBR2 KO NK cells for certain conditions. Although specific safety data for this treatment remains limited, some research indicates that side effects might include mild flu-like symptoms, such as fever or chills, as the body responds to the treatment.

Most treatments for oral premalignant lesions involve surgical removal or topical therapies. But TROP2 CAR/IL-15 TGFBR2 KO NK cells work differently, targeting cancerous cells using genetically modified natural killer (NK) cells. These cells are engineered to express a chimeric antigen receptor (CAR) for TROP2, a protein often overexpressed in premalignant lesions, and include an interleukin-15 (IL-15) component to enhance their activity. Additionally, the TGFBR2 knockout (KO) feature helps these NK cells escape the suppressive tumor environment. Researchers are excited because this approach not only targets the lesions more directly but also potentially boosts the immune system's ability to fight abnormal cells, offering a novel mechanism that could improve outcomes.

Studies have shown that TROP2 CAR/IL-15 NK cells can effectively kill cancer cells and strengthen the immune system. IL-15, a protein, enhances immune system function. Preclinical studies have found these cells effective and safe for treating ovarian and pancreatic cancers. Researchers believe targeting TROP2, a protein on some cancer cells, will improve outcomes in various cancers. Although the clinical benefits are still under investigation, early results show promise in enhancing the immune response against cancer. Participants in this trial will receive TROP2 CAR/IL-15 TGFBR2 KO NK cells to evaluate their effectiveness and safety for oral premalignant lesions.¹²³⁴⁶